“Pre-Filled Device Manufacturing market set to grow to $7.5bn by 2022” says new visiongain report

13 November 2018
Pharma

Visiongain has launched a new pharma report Top Pre-Filled Injection Device Manufacturers 2018-2028: Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Filling Services.

Pre-filled syringes provide users with a number of advantages over other drug delivery systems. These include simplified storage and disposal, shorter preparation and administration time and reduced risk of medication errors. For drug manufacturers, there are also numerous advantages to pre-filled syringes. Filling syringes rather than vials cuts overfill rates, reducing wastage, and also eliminates material costs as there is no need for vials as well as syringes. However, challenges still exist in the use of pre-filled syringes. These include the administration of high viscosity drugs, including some biologics, as well as larger injection volumes. This growing market will be led by pharmaceutical and biotechnology companies looking to differentiate their novel therapies while meeting the requirements for patient self-administration and increasingly stringent safety legislation.

The lead analyst of the report commented "The pharmaceutical industry will shift towards novel biotech medicines that will need injectable delivery systems and this will increase demand for pre-filled syringe systems. Companies that have a broader range of platforms to accommodate differing needs will be better-placed to respond to this demand. Increased interest in biosimilars will also drive growth in the pre-filled injection device market."

Leading companies featured in the report include Aptar Stelmi, Becton, Dickinson, & Co (BD), Bespak Injectables, Boehringer Ingelheim, Catalent, Dätwyler Holding, Gerresheimer, Haselmeier, Laboratorios Farmacéuticos ROVI and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever